Cite
HARVARD Citation
Clark, R. et al. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet. 4 (7), pp. e310-e316. [Online].